Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: GSK pursues M&A to boost pipeline; US decision affects Alzheimer’s candidates; Boehringer Ingelheim’s hopes for Jardiance; Japan rebuilds generic supplies; and a look at key upcoming trial readouts.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 15 April 2022, including: GlaxoSmithKline plc pursues M&A to boost pipeline; US decision affects Alzheimer’s candidates; Boehringer Ingelheim GmbH’s hopes for Jardiance; Japan looks to rebuild generic supplies; and a look at key upcoming trial readouts.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Another New Home For Momelotinib As GSK Buys Sierra" - Scrip, 13 Apr, 2022.)

(Also see "Biogen’s Aduhelm Competitors Boosted By Final CMS Coverage Decision" - Scrip, 9 Apr, 2022.)

(Also see "Boehringer Pharma Chief Confident Of Continued Success For Jardiance" - Scrip, 12 Apr, 2022.)

(Also see "A Year's Struggle: How Japan Is Recovering Damaged Generic Supplies After Quality Violations" - Scrip, 12 Apr, 2022.)

(Also see "Four Major Clinical Trial Readouts To Watch Out For In Q2" - Scrip, 12 Apr, 2022.)

 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel